CN105717147A - Model for predicating lung cancer risks for people suffering from pulmonary nodules among China urban population on basis of CT (computed tomography) images and biomarker spectrums - Google Patents
Model for predicating lung cancer risks for people suffering from pulmonary nodules among China urban population on basis of CT (computed tomography) images and biomarker spectrums Download PDFInfo
- Publication number
- CN105717147A CN105717147A CN201610187933.5A CN201610187933A CN105717147A CN 105717147 A CN105717147 A CN 105717147A CN 201610187933 A CN201610187933 A CN 201610187933A CN 105717147 A CN105717147 A CN 105717147A
- Authority
- CN
- China
- Prior art keywords
- value
- biomarker
- solution
- serum
- sex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/02—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material
- G01N23/04—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material and forming images of the material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Abstract
The invention discloses a model for predicating lung cancer risks for people suffering from pulmonary nodules among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The model comprises biomarkers, enzyme-labeled antibodies of the biomarkers, a carbonate buffer solution with the pH value being 9.6, a phosphate buffer solution with a pH value being 7.4, a serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, serum of normal people and positive control serum; the biomarkers are four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens and are combined with CT imageology parameters and other clinical indexes. The model can assist in screening of lung cancer.
Description
Technical field
The present invention relates to biological technical field, specifically, be a kind of compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker.
Background technology
Pulmonary carcinoma is common in world wide and is the highest cancer of fatality rate.All occupy first of each malignant tumor in China's lung cancer morbidity rate and mortality rate.According to World Health Organization (WHO) world institute of oncology (TheInternationalAgencyforResearchonCancer, IARC) statistics, China's lung cancer morbidity rate in 2008 is 35/,100,000 people, and this mechanism estimated to 2025, and China will increase pulmonary carcinoma 1,000,000 example every year newly.According to Ministry of Public Health health statistics yearbook in 2010, ending 2009, whole nation lung cancer mortality is 30.83/10 ten thousand people, exceedes 4/,100,000 people higher than the hepatocarcinoma of the second high mortality.Although survival rate only had 15% in the 5 of pulmonary carcinoma years, but account for its 5 years survival rates of the patient that early diagnosis is pulmonary carcinoma of 16% and can reach 49%, it is seen that early diagnosis is the key factor improving patients with lung cancer survival rate.
Lung neoplasm is the Early signs on a kind of iconography of pulmonary carcinoma, but not every Lung neoplasm all can finally develop into pulmonary carcinoma.Increasing along with urban population, day by day increasing the weight of of environmental pollution, pulmonary carcinoma is significantly higher than rural population at the sickness rate of urban population.Along with the extensive examination being carried out pulmonary carcinoma in high-risk group by low-dose CT examination, increasing early stage of lung cancer patient is found in time being in the Lung neoplasm stage, and significantly reduces because of the mortality rate caused by pulmonary carcinoma.CT image technology examination pulmonary carcinoma in High Risk of Lung Cancer crowd has hypersensitivity, but specificity limits to relatively, and most of tuberositys that namely examination goes out are likely benign protuberance, not only increases the economic expenditure of society's examination pulmonary carcinoma, too increases the burden of patients ' psychological simultaneously.By combining the feature of the high specific of biomarker spectrum, it is possible to make up the limitation of CT examination pulmonary carcinoma, there is higher sensitivity simultaneously.Invent the pernicious risk forecast model of Lung neoplasm for American-European crowd at present in the world, and the pernicious risk model of Lung neoplasm for Chinese population there is not yet report.
Summary of the invention
It is an object of the invention to for deficiency of the prior art, it is provided that a kind of compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker.
Another purpose of the present invention is to provide the purposes of cancer risk assessment model described above.
Another the purpose of the present invention is to provide a kind of composes the cancer risk assessment test kit for Chinese city population Lung neoplasm crowd based on CT image and biomarker.
For achieving the above object, the present invention adopts the technical scheme that:
A kind of compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker, the reagent including measuring following four biomarker Serum protein expression: gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and squamous cell carcinoma antigen.
Preferably, described cancer risk assessment model is by biomarker and enzyme labelled antibody thereof, and pH value is the carbonate buffer solution of 9.6, pH value is the phosphate buffer of 7.4, serum albumin diluent, stop buffer, tetramethyl benzidine substrate solution, normal human serum and positive control serum composition；Wherein, described biomarker is include gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and squamous cell carcinoma antigen, and and other clinical indices combination.
Preferably, described pH value is that the carbonate buffer solution of 9.6 is for adding to obtain 1.59 grams of sodium carbonate and 2.93 grams of sodium bicarbonate in 1L distilled water.
Preferably, described pH value is that the phosphate buffer of 7.4 is for adding to obtain 0.2 gram of biphosphate, 2.9 grams of disodium hydrogen phosphate dodecahydrates, 8.0 grams of sodium chloride, 0.2 gram of potassium chloride, 0.5mL tween 20s in 1L distilled water.
Preferably, described serum albumin diluent is that 0.1 gram of Ox blood serum, sheep blood serum or rabbit serum proteins add to the phosphate buffer that 100mLpH value is 7.4 and obtain.
Preferably, described stop buffer is 2M sulfuric acid solution.
Preferably, described tetramethyl benzidine substrate solution is 0.5mL concentration is the ethanol solution of the tetramethyl benzidine of 2mg/mL, and 10mLpH value is substrate buffer solution and the 32uL concentration of 5.0 is that the aqueous hydrogen peroxide solution of 0.75vol% is obtained by mixing；
Wherein, described pH value is the substrate buffer solution of 5.0 is the distilled water solution containing 0.2M disodium hydrogen phosphate and 0.1M citric acid.
Described forecast model also includes the carrier recording following evaluation method:
Pernicious risk probability=ex/(1+ex)
Wherein, X=-5.6017+ (0.0264 × age)+(8.8539 × smoking)+(0.1859 × tuberosity diameter)+(3.1865 × spicule sign)+(-8.7109 × sex)+(-0.00001 × ProGRP)+(0.0057 × SCC-Ag)+(0.1686 × CYFRA21-1)+(-0.00311 × CEA)；
Previously there are smoking history, smoking=1, previously non-smoking history, smoking=0；Jagged levying, spicule sign=1, impulse-free robustness is levied, burr=0；Sex is male, sex=1, and sex is women, sex=0.
Tuberosity diameter (mm), spicule sign obtain according to CT imaging Analysis.
When pernicious risk probability≤0.22, for low danger；When pernicious risk probability > 0.22 and≤0.94 time be middle danger；And when pernicious probability > 0.94 time, for high-risk.
For realizing above-mentioned second purpose, the present invention adopts the technical scheme that:
The forecast model as above application in preparing cancer risk assessment test kit.
Preferably, the detection of described risk profile is directed to Chinese city population.
For realizing above-mentioned 3rd purpose, the present invention adopts the technical scheme that:
A kind of compose the cancer risk assessment test kit for Chinese city population Lung neoplasm crowd based on CT image and biomarker, by biomarker and enzyme labelled antibody thereof, pH value is the carbonate buffer solution of 9.6, pH value is the phosphate buffer of 7.4, serum albumin diluent, stop buffer, tetramethyl benzidine substrate solution, normal human serum and positive control serum composition；Described biomarker is gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and squamous cell carcinoma antigen.
Described test kit also includes the carrier recorded such as drag and evaluation method:
Pernicious risk probability=ex/(1+ex)
Wherein, X=-5.6017+ (0.0264 × age)+(8.8539 × smoking)+(0.1859 × tuberosity diameter)+(3.1865 × spicule sign)+(-8.7109 × sex)+(-0.00001 × ProGRP)+(0.0057 × SCC-Ag)+(0.1686 × CYFRA21-1)+(-0.00311 × CEA)；
Previously there are smoking history, smoking=1, previously non-smoking history, smoking=0；Jagged levying, spicule sign=1, impulse-free robustness is levied, burr=0；Sex is male, sex=1, and sex is women, sex=0.
Tuberosity diameter (mm), spicule sign obtain according to CT imaging Analysis.
When pernicious risk probability≤0.22, for low danger；When pernicious risk probability > 0.22 and≤0.94 time be middle danger；And when pernicious probability > 0.94 time, for high-risk.
Preferably, described pH value is that the carbonate buffer solution of 9.6 is for adding to obtain 1.59 grams of sodium carbonate and 2.93 grams of sodium bicarbonate in 1L distilled water；Described pH value is that the phosphate buffer of 7.4 is for adding to obtain 0.2 gram of potassium dihydrogen phosphate, 2.9 grams of disodium hydrogen phosphate dodecahydrates, 8.0 grams of sodium chloride, 0.2 gram of potassium chloride, 0.5mL tween 20s in 1L distilled water；Described serum albumin diluent is that 0.1 gram of Ox blood serum, sheep blood serum or rabbit serum proteins add to the phosphate buffer that 100mLpH value is 7.4 and obtain；Described stop buffer is 2M sulfuric acid solution；Described tetramethyl benzidine substrate solution is 0.5mL concentration is the ethanol solution of the tetramethyl benzidine of 2mg/mL, 10mLpH value is substrate buffer solution and the 32uL concentration of 5.0 is that the aqueous hydrogen peroxide solution of 0.75vol% is obtained by mixing, and described pH value is the substrate buffer solution of 5.0 is the distilled water solution containing 0.2M disodium hydrogen phosphate and 0.1M citric acid.
The invention have the advantage that
1, present invention firstly provides 4 kinds of biomarkers including gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and squamous cell carcinoma antigen and CT iconography parameter and the combination of other clinical indices and can become the leading indicator of screening lung cancer.
2, include gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and 4 kinds of biomarkers of squamous cell carcinoma antigen and CT iconography parameter and other clinical indices combines the low dosage breast CT index being relatively currently used for examination pulmonary carcinoma as prediction index and other clinical indices is more objective, and it is simple, easy, reliable to measure this type of biomarker expression level.
Accompanying drawing explanation
Accompanying drawing 1 is compose the cancer risk assessment model ROC curve to high-risk group based on CT image and biomarker.
Accompanying drawing 2 is that the cancer risk assessment model ROC curve of high-risk group is compared by LCBP with American Thoracic doctors'associations (ACCP).
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate the present invention rather than restriction the scope of the present invention.In addition, it is to be understood that after having read the content that the present invention records, the present invention can be made various changes or modifications by those skilled in the art, and these equivalent form of values fall within the application appended claims limited range equally.
Embodiment 1
A kind of compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker, by biomarker and enzyme labelled antibody thereof, pH value is the carbonate buffer solution of 9.6, pH value is the phosphate buffer of 7.4, serum albumin diluent, stop buffer, tetramethyl benzidine substrate solution, normal human serum and positive control serum composition；
Described biomarker is include gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and squamous cell carcinoma antigen.
Described pH value is that the carbonate buffer solution of 9.6 is for adding to obtain 1.59 grams of sodium carbonate and 2.93 grams of sodium bicarbonate in 1L distilled water.Described pH value is that the phosphate buffer of 7.4 is for adding to obtain 0.2 gram of potassium dihydrogen phosphate, 2.9 grams of disodium hydrogen phosphate dodecahydrates, 8.0 grams of sodium chloride, 0.2 gram of potassium chloride, 0.5mL tween 20s in 1L distilled water.Described serum albumin diluent is that 0.1 gram of Ox blood serum, sheep blood serum or rabbit serum proteins add to the phosphate buffer that 100mLpH value is 7.4 and obtain.Described stop buffer is 2M sulfuric acid solution.Described tetramethyl benzidine substrate solution is 0.5mL concentration is the ethanol solution of the tetramethyl benzidine of 2mg/mL, 10mLpH value is substrate buffer solution and the 32uL concentration of 5.0 is that the aqueous hydrogen peroxide solution of 0.75vol% is obtained by mixing, and described pH value is the substrate buffer solution of 5.0 is the distilled water solution containing 0.2M disodium hydrogen phosphate and 0.1M citric acid.
The using method of mentioned reagent box is as follows:
1, it is coated: with the carbonate buffer solution that 0.05MpH value is 9.6, biomarker being diluted to protein content is 1-10ug/mL.The reacting hole of each polystyrene adds 0.1mL, in 4 DEG C overnight.Next day, discard solution in hole, wash 3 times with the phosphate buffer that pH value is 7.4, each 3 minutes.
2, application of sample: add the measuring samples after certain serum albumin diluted, normal human serum and positive control serum 0.1mL respectively to above-mentioned coated reacting hole, put 37 DEG C hatch 1 hour after wash 3 times with the phosphate buffer that pH value is 7.4, each 3 minutes.
3, add horseradish peroxidase labeling antibody: in each reacting hole, add the horseradish peroxidase labeling antibody 0.1mL of diluted fresh, 37 DEG C hatch 0.5-1 hour after wash 3 times with the phosphate buffer that pH value is 7.4, each 3 minutes.
4, substrate solution colour developing is added: in each reacting hole, add tetramethyl benzidine substrate solution 0.1mL, at 37 DEG C, hatch 10-30 minute.
5, reaction is terminated: in each reacting hole, add 2M sulphuric acid 0.05mL.
6, result judges: on ELISA detector, in 450nm place, surveys each hole OD value after returning to zero with blank control wells.If more than the negative control OD value 2.1 times of regulation, being the positive.
Using normal control product protein expression level as criterion, ratio, divided by this standard, so that it is determined that patient's proteinogram is relative to the expression ratio of normal person, is substituted in following formula, calculates pernicious risk probability by Serum of Patients with Lung Cancer proteinogram expression respectively.
Pernicious risk probability=ex/(1+ex)
X=-5.6017+ (0.0264 × age)+(8.8539 × smoking)+(0.1859 × tuberosity diameter)+(3.1865 × spicule sign)+(-8.7109 × sex)+(-0.00001 × ProGRP)+(0.0057 × SCC-Ag)+(0.1686 × CYFRA21-1)+(-0.00311 × CEA)
When pernicious risk probability≤0.22, for low danger；When pernicious risk probability > 0.22 and≤0.94 time be middle danger；And when pernicious probability > 0.94 time, for high-risk.
This model sensitivity is 94.6%, and specificity is 94.2%.
Wherein, previously there are smoking history, smoking=1, previously non-smoking history, smoking=0；Jagged levying, spicule sign=1, impulse-free robustness is levied, burr=0；Sex is male, sex=1, and sex is women, sex=0.
Tuberosity diameter (mm), spicule sign obtain according to CT imaging Analysis.
The present invention determines, through clinic, the urban population 342 example patient having Lung neoplasm by collecting, and eventually through definitive pathological diagnosis pulmonary carcinoma 262 example, has been sampled 111 example Serum of Patients with Lung Cancers by method of randomization；Simultaneously in 80 Serum Banks being diagnosed as optimum Lung neoplasm patient, sampled the 52 optimum Lung neoplasm serum of example by method of randomization.4 kinds of biomarkers in the sub-immunodetection detection serum of applied chemistry luminous particle, gather the clinical informations such as patient age, smoking history, tuberosity diameter, spicule sign, sex simultaneously.Obtain model sensitivity and specificity as shown in table 1.
Table 1 composes the cancer risk assessment model validation for Chinese city population Lung neoplasm crowd based on CT image and biomarker
Accompanying drawing 2 is that the cancer risk assessment model ROC curve of high-risk group is compared (p < 0.01) with American Thoracic doctors'associations (ACCP) by LCBP
The above is only the preferred embodiment of the present invention; it should be pointed out that, for those skilled in the art, under the premise without departing from the inventive method; can also making some improvement and supplement, these improve and supplement and also should be regarded as protection scope of the present invention.
Claims (10)
1. compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker for one kind, it is characterized in that, the reagent including measuring following four biomarker Serum protein expression: gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and squamous cell carcinoma antigen.
2. according to claim 1 compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker, it is characterized in that, including four kinds of biomarkers described in claim 1 and enzyme labelled antibody thereof, pH value be 9.6 carbonate buffer solution, pH value be 7.4 phosphate buffer, serum albumin diluent, stop buffer and tetramethyl benzidine substrate solution.
3. according to claim 1 compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker, it is characterised in that described forecast model also includes following reagent: normal human serum and positive control serum.
4. according to claim 1 compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker, it is characterised in that described forecast model also includes the carrier recording following evaluation method:
Pernicious risk probability=ex/(1+ex)；
Wherein, X=-5.6017+ (0.0264 × age)+(8.8539 × smoking)+(0.1859 × tuberosity diameter)+(3.1865 × spicule sign)+(-8.7109 × sex)+(-0.00001 × ProGRP)+(0.0057 × SCC-Ag)+(0.1686 × CYFRA21-1)+(-0.00311 × CEA)；
Previously there are smoking history, smoking=1, previously non-smoking history, smoking=0；Jagged levying, spicule sign=1, impulse-free robustness is levied, burr=0；Sex is male, sex=1, and sex is women, sex=；
Tuberosity diameter (mm), spicule sign obtain according to CT imaging Analysis；
When pernicious risk probability≤0.22, for low danger；When pernicious risk probability > 0.22 and≤0.94 time be middle danger；And when pernicious probability > 0.94 time, for high-risk.
5. according to claim 2 compose the cancer risk assessment model for Chinese city population Lung neoplasm crowd based on CT image and biomarker, it is characterized in that, described pH value is that the carbonate buffer solution of 9.6 is for adding to obtain 1.59 grams of sodium carbonate and 2.93 grams of sodium bicarbonate in 1L distilled water；Described pH value is that the phosphate buffer of 7.4 is for adding to obtain 0.2 gram of potassium dihydrogen phosphate, 2.9 grams of disodium hydrogen phosphate dodecahydrates, 8.0 grams of sodium chloride, 0.2 gram of potassium chloride, 0.5mL tween 20s in 1L distilled water；Described serum albumin diluent is that 0.1 gram of Ox blood serum, sheep blood serum or rabbit serum proteins add to the phosphate buffer that 100mLpH value is 7.4 and obtain；Described stop buffer is 2M sulfuric acid solution；Described tetramethyl benzidine substrate solution is 0.5mL concentration is the ethanol solution of the tetramethyl benzidine of 2mg/mL, 10mLpH value is substrate buffer solution and the 32uL concentration of 5.0 is that the aqueous hydrogen peroxide solution of 0.75vol% is obtained by mixing, and described pH value is the substrate buffer solution of 5.0 is the distilled water solution containing 0.2M disodium hydrogen phosphate and 0.1M citric acid.
6. claim 1-5 arbitrary described forecast model application in preparing cancer risk assessment test kit.
7. application according to claim 6, it is characterised in that the detection of described risk profile is directed to Chinese city population.
8. compose the cancer risk assessment test kit for Chinese city population Lung neoplasm crowd based on CT image and biomarker for one kind, it is characterized in that, by biomarker and enzyme labelled antibody thereof, pH value is the carbonate buffer solution of 9.6, pH value is the phosphate buffer of 7.4, serum albumin diluent, stop buffer, tetramethyl benzidine substrate solution, normal human serum and positive control serum composition；Described biomarker is gastrin release propetide, carcinoembryonic antigen, the fragment of Cyfra21-1 and squamous cell carcinoma antigen.
9. compose the cancer risk assessment test kit for Chinese city population Lung neoplasm crowd based on CT image and biomarker according to claim 8, it is characterized in that, described pH value is that the carbonate buffer solution of 9.6 is for adding to obtain 1.59 grams of sodium carbonate and 2.93 grams of sodium bicarbonate in 1L distilled water；Described pH value is that the phosphate buffer of 7.4 is for adding to obtain 0.2 gram of potassium dihydrogen phosphate, 2.9 grams of disodium hydrogen phosphate dodecahydrates, 8.0 grams of sodium chloride, 0.2 gram of potassium chloride, 0.5mL tween 20s in 1L distilled water；Described serum albumin diluent is that 0.1 gram of Ox blood serum, sheep blood serum or rabbit serum proteins add to the phosphate buffer that 100mLpH value is 7.4 and obtain；Described stop buffer is 2M sulfuric acid solution；Described tetramethyl benzidine substrate solution is 0.5mL concentration is the ethanol solution of the tetramethyl benzidine of 2mg/mL, 10mLpH value is substrate buffer solution and the 32uL concentration of 5.0 is that the aqueous hydrogen peroxide solution of 0.75vol% is obtained by mixing, and described pH value is the substrate buffer solution of 5.0 is the distilled water solution containing 0.2M disodium hydrogen phosphate and 0.1M citric acid.
10. compose the cancer risk assessment test kit for Chinese city population Lung neoplasm crowd based on CT image and biomarker according to claim 8, it is characterised in that described test kit also includes the carrier recorded such as drag and evaluation method:
Pernicious risk probability=ex/(1+ex)
Wherein, X=-5.6017+ (0.0264 × age)+(8.8539 × smoking)+(0.1859 × tuberosity diameter)+(3.1865 × spicule sign)+(-8.7109 × sex)+(-0.00001 × ProGRP)+(0.0057 × SCC-Ag)+(0.1686 × CYFRA21-1)+(-0.00311 × CEA)；
Previously there are smoking history, smoking=1, previously non-smoking history, smoking=0；Jagged levying, spicule sign=1, impulse-free robustness is levied, burr=0；Sex is male, sex=1, and sex is women, sex=0；
Tuberosity diameter (mm), spicule sign obtain according to CT imaging Analysis；
When pernicious risk probability≤0.22, for low danger；When pernicious risk probability > 0.22 and≤0.94 time be middle danger；And when pernicious probability > 0.94 time, for high-risk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610187933.5A CN105717147B (en) | 2016-03-29 | 2016-03-29 | A kind of cancer risk assessment kit being directed to Chinese city population Lung neoplasm crowd based on CT images and biomarker spectrum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610187933.5A CN105717147B (en) | 2016-03-29 | 2016-03-29 | A kind of cancer risk assessment kit being directed to Chinese city population Lung neoplasm crowd based on CT images and biomarker spectrum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105717147A true CN105717147A (en) | 2016-06-29 |
| CN105717147B CN105717147B (en) | 2018-11-23 |
Family
ID=56158374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610187933.5A Active CN105717147B (en) | 2016-03-29 | 2016-03-29 | A kind of cancer risk assessment kit being directed to Chinese city population Lung neoplasm crowd based on CT images and biomarker spectrum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105717147B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107292114A (en) * | 2017-06-28 | 2017-10-24 | 中日友好医院 | A kind of method for building up of the pernicious Probabilistic Prediction Model of solitary pulmonary nodule |
| CN108461144A (en) * | 2017-12-21 | 2018-08-28 | 深圳大学 | Chinese population low-level radiation suffers from the appraisal procedure and system of cancer risk |
| CN110223776B (en) * | 2019-07-15 | 2021-01-01 | 四川大学华西医院 | Lung cancer risk prediction system |
| CN113707224A (en) * | 2021-08-30 | 2021-11-26 | 东南大学 | Cross-scale integration assessment pulmonary nodule malignancy risk prediction system |
| CN115082437A (en) * | 2022-07-22 | 2022-09-20 | 浙江省肿瘤医院 | Tumor prediction system and method based on tongue picture image and tumor marker and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138074A (en) * | 2008-07-03 | 2011-07-27 | 霍夫曼-拉罗奇有限公司 | ASC as a marker for lung cancer |
| CN102317784A (en) * | 2008-12-22 | 2012-01-11 | 霍夫曼-拉罗奇有限公司 | ARMET as cancer markers |
-
2016
- 2016-03-29 CN CN201610187933.5A patent/CN105717147B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138074A (en) * | 2008-07-03 | 2011-07-27 | 霍夫曼-拉罗奇有限公司 | ASC as a marker for lung cancer |
| CN102317784A (en) * | 2008-12-22 | 2012-01-11 | 霍夫曼-拉罗奇有限公司 | ARMET as cancer markers |
Non-Patent Citations (2)
| Title |
|---|
| DA-WEIYANG ET AL: "Risk stratification of patients using the lung cancer biomarker panel in China(lcbp)", 《ATS JOURNALS》 * |
| DA-WEIYANG ET AL: "Role of a Serum-Based Biomarker Panel in the Early Diagnosis of Lung Cancer for a Cohort of High-Risk Patients", 《CANCER》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107292114A (en) * | 2017-06-28 | 2017-10-24 | 中日友好医院 | A kind of method for building up of the pernicious Probabilistic Prediction Model of solitary pulmonary nodule |
| CN107292114B (en) * | 2017-06-28 | 2020-07-14 | 中日友好医院 | Establishing method of solitary pulmonary nodule malignancy probability prediction model |
| CN108461144A (en) * | 2017-12-21 | 2018-08-28 | 深圳大学 | Chinese population low-level radiation suffers from the appraisal procedure and system of cancer risk |
| CN110223776B (en) * | 2019-07-15 | 2021-01-01 | 四川大学华西医院 | Lung cancer risk prediction system |
| CN113707224A (en) * | 2021-08-30 | 2021-11-26 | 东南大学 | Cross-scale integration assessment pulmonary nodule malignancy risk prediction system |
| CN115082437A (en) * | 2022-07-22 | 2022-09-20 | 浙江省肿瘤医院 | Tumor prediction system and method based on tongue picture image and tumor marker and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105717147B (en) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105717146A (en) | Kit for predicating lung cancer risk for high-risk groups among China urban population on basis of CT (computed tomography) images and biomarker spectrums | |
| CN105717147A (en) | Model for predicating lung cancer risks for people suffering from pulmonary nodules among China urban population on basis of CT (computed tomography) images and biomarker spectrums | |
| Pasricha et al. | Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors | |
| CN112362871B (en) | Biomarker for esophageal cancer and application thereof | |
| Wang et al. | Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer | |
| CN104316685B (en) | Diacetyl spermine detection kit and preparation method and application thereof | |
| He et al. | Measurement of circulating 25-hydroxy vitamin d using three commercial enzyme-linked immunosorbent assay kits with comparison to liquid chromatography: tandem mass spectrometry method | |
| Linkov et al. | Reliability of tumor markers, chemokines, and metastasis-related molecules in serum | |
| CN110187109A (en) | A kind of autoantibody joint-detection ELISA kit for Grades of Gastric Cardia Adenocarcinoma early screening | |
| CN108351358A (en) | Liver cancer test method | |
| Bartuli et al. | Podoplanin in the development and progression of oral cavity cancer: a preliminary study | |
| Fang et al. | The evaluation of serum biomarkers for non-small cell lung cancer (NSCLC) diagnosis | |
| CN106771258A (en) | The detection kit and its methods and applications of a kind of M2BP | |
| JPH0296658A (en) | Early detecting method of lung cancer | |
| TWI408370B (en) | A serological maker for detecting pancreatic cancer and a method for using the serological maker | |
| CN109507426A (en) | Prostate cancer diagnosis, classification or prognostic marker, detection reagent or kit, system and its application | |
| CN105891482B (en) | A kind of cancer risk assessment model based on biomarker spectrum for China Rural Population Lung neoplasm crowd | |
| JP2018080943A (en) | Method of detecting nash | |
| CN109142729A (en) | A kind of anti-HMGB3 autoantibody of lung cancer marker and its application | |
| Cooper et al. | A solid phase radioimmunoassay for prostatic acid phosphatase | |
| Nunes et al. | Risk factors associated with disease-specific mortality in papillary thyroid cancer patients with distant metastases | |
| CN110187111A (en) | One kind being used for early cardiac cancer screening ELISA kit | |
| CN105759062A (en) | Biomarker-spectrum-based lung cancer risk prediction kit for high-risk groups in rural China | |
| CN108548923A (en) | Small cell carcinoma of lung earlier specificity autoantibody panel diagnostic kits | |
| CN102375057A (en) | Method for simultaneously detecting a plurality of serum markers by homogeneous fluorescence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160629 Assignee: Abbott Trading (Shanghai) Co.,Ltd. Assignor: ZHONGSHAN HOSPITAL, FUDAN University Contract record no.: X2021980012558 Denomination of invention: A lung cancer risk prediction kit for Chinese urban population with pulmonary nodules based on CT image and biomarker spectrum Granted publication date: 20181123 License type: Common License Record date: 20211116 |
|
| EE01 | Entry into force of recordation of patent licensing contract |